333 related articles for article (PubMed ID: 29202874)
21. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
22. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
23. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
24. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
[TBL] [Abstract][Full Text] [Related]
25. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
26. Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations.
Sarmati L; Nicastri E; Parisi SG; D'Ettorre G; Narciso P; Mancino G; Gallo I; Abbadessa V; Dalle NE; Traina C; Vullo V; Andreoni M
J Med Virol; 2001 Dec; 65(4):631-6. PubMed ID: 11745924
[TBL] [Abstract][Full Text] [Related]
27. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
28. Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
Gupta RK; Ford D; Mulenga V; Walker AS; Kabamba D; Kalumbi M; Grant PR; Ferrier A; Pillay D; Gibb DM; Chintu C
Pediatr Infect Dis J; 2010 Aug; 29(8):e57-62. PubMed ID: 20508547
[TBL] [Abstract][Full Text] [Related]
29. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
Shulman NS; Hughes MD; Winters MA; Shafer RW; Zolopa AR; Hellmann NS; Bates M; Whitcomb JM; Katzenstein DA
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):121-7. PubMed ID: 12394789
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
31. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
[TBL] [Abstract][Full Text] [Related]
32. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
[TBL] [Abstract][Full Text] [Related]
33. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
34. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Luo XL; Mo LD; Su GS; Huang JP; Wu JY; Su HZ; Huang WH; Luo SD; Ni ZY
J Pharmacol Sci; 2019 Apr; 139(4):275-279. PubMed ID: 30928089
[TBL] [Abstract][Full Text] [Related]
35. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies.
Moyle G; Sawyer W; Law M; Amin J; Hill A
Clin Ther; 2004 Jan; 26(1):92-7. PubMed ID: 14996521
[TBL] [Abstract][Full Text] [Related]
36. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
[TBL] [Abstract][Full Text] [Related]
37. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.
Paolucci S; Baldanti F; Maserati R; Castelli F; Suter F; Maggiolo F; Pan A; Gerna G
Antiviral Res; 2000 Feb; 45(2):101-14. PubMed ID: 10809019
[TBL] [Abstract][Full Text] [Related]
38. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
[TBL] [Abstract][Full Text] [Related]
39. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
García-Lerma JG; MacInnes H; Bennett D; Reid P; Nidtha S; Weinstock H; Kaplan JE; Heneine W
J Virol; 2003 May; 77(10):5685-93. PubMed ID: 12719561
[TBL] [Abstract][Full Text] [Related]
40. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
